RxDoctor Payments Data

Daniel Paoletti, PA

Medical · Oxford, CTNPI 1023441193

Payments from drug & device makers

$2,171in general payments, 2019–2025

Across 103 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$624
  • Merck$388
  • Pfizer$279
  • Lilly USA, LLC$252
  • Boehringer Ingelheim$213
  • Amgen$98
  • plus $317 from 5 others

What the payments were for

  • Food & beverage$2,171100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,171 in reported general payments places this provider in the 80th percentile of 592 medical providers in Connecticut.

See all medical providers in Connecticut

Medicare billing

Part B allowed, 2024
$4,571
Medicare patients
34
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban290$376,702
EntrestoSacubitril/Valsartan58$79,733
XareltoRivaroxaban38$62,955
JardianceEmpagliflozin41$47,530
BrilintaTicagrelor15$19,119
Repatha SureclickEvolocumab15$16,536
Metoprolol Succinate219$2,566
Diltiazem 24hr Er (Cd)Diltiazem Hcl99$2,417
Rosuvastatin Calcium139$2,055
Atorvastatin Calcium169$1,918
Amlodipine Besylate220$1,417
Nitroglycerin PatchNitroglycerin16$1,381
Potassium Chloride22$1,377
Ranolazine ErRanolazine14$1,063
Furosemide188$964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$279$376,702290 claims
NovartisEntresto$89$79,73358 claims
Boehringer IngelheimJardiance$213$47,53041 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 592 medical providers in Connecticut.

Other medical in Oxford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →